According to the guidelines by the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology, National Comprehensive Cancer Network and European Organisation for Research and Treatment of Cancer, it is important to evaluate both chemotherapy regimen risk and patient-specific risk factors when evaluating the risk of FN, and hence, the potential need for prophylactic G-CSF use [7–10]. Here, CSF3 is linked to cancer.